📣 VC round data is live. Check it out!

Suraksha Diagnostics Valuation Multiples

Discover Suraksha Diagnostics' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Hyperfine, Biodesix, Centrum Medyczne ENEL-MED, Bioneer and more.

Suraksha Diagnostics Overview

About Suraksha Diagnostics

Suraksha Diagnostic Ltd offers a one-stop integrated solution for pathology and radiology testing, and medical consultation services to its customers through its extensive operational network, consisting of its flagship central reference laboratory, satellite laboratories, and customer touchpoints which include diagnostic centres and sample collection centres across the states of West Bengal, Bihar, Assam, and Meghalaya.


Founded

2005

HQ

India

Employees

1.3K

Financials (LTM)

Revenue: $31M
EBITDA: $10M

EV

$165M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Suraksha Diagnostics Financials

Suraksha Diagnostics reported last 12-month revenue of $31M and EBITDA of $10M.

In the same LTM period, Suraksha Diagnostics generated $10M in EBITDA and $4M in net income.

Revenue (LTM)


Suraksha Diagnostics P&L

In the most recent fiscal year, Suraksha Diagnostics reported revenue of $33M and EBITDA of $10M.

Suraksha Diagnostics is profitable as of last fiscal year, with gross margin of 88%, EBITDA margin of 32%, and net margin of 11%.

See analyst estimates for Suraksha Diagnostics
LTMLast FY202320242025202620272028
Revenue$31M$33M$22M$26M$31M
Gross Profit-$29M$19M$23M$27M
Gross Margin-88%87%88%88%
EBITDA$10M$10M$7M$9M$10M
EBITDA Margin31%32%31%34%32%
EBIT Margin17%18%16%19%18%
Net Profit$4M$4M$2M$3M$3M
Net Margin12%11%9%12%11%

Financial data powered by Morningstar, Inc.

Suraksha Diagnostics Stock Performance

Suraksha Diagnostics has current market cap of $154M, and enterprise value of $165M.

Market Cap Evolution


Suraksha Diagnostics' stock price is $2.97.

Suraksha Diagnostics share price decreased by 1.4% in the last 30 days, and by 15.8% in the last year.

Suraksha Diagnostics has an EPS (earnings per share) of $0.07.

See more trading valuation data for Suraksha Diagnostics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$165M$154M-1.4%-1.4%21.5%-15.8%$0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Suraksha Diagnostics Valuation Multiples

Suraksha Diagnostics trades at 5.3x EV/Revenue multiple, and 17.0x EV/EBITDA.

See NTM and 2027E valuation multiples for Suraksha Diagnostics

EV / Revenue (LTM)


Suraksha Diagnostics Financial Valuation Multiples

As of June 2, 2026, Suraksha Diagnostics has market cap of $154M and EV of $165M.

Suraksha Diagnostics has a P/E ratio of 42.0x.

LTMLast FY202320242025202620272028
EV/Revenue5.3x5.1x7.4x6.4x5.3x
EV/EBITDA17.0x15.9x23.6x19.1x16.5x
EV/EBIT30.9x28.9x45.4x33.1x29.5x
EV/Gross Profit-5.7x8.5x7.3x6.0x
P/E42.0x43.4x75.8x49.3x45.7x
EV/FCF111.2x108.4x80.2x78.7x97.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Suraksha Diagnostics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Suraksha Diagnostics Margins & Growth Rates

Suraksha Diagnostics grew revenue by 8% and EBITDA by 7% in the last fiscal year.

In the most recent fiscal year, Suraksha Diagnostics reported gross margin of 88%, EBITDA margin of 32%, and net margin of 11%.

See estimated margins and future growth rates for Suraksha Diagnostics

Suraksha Diagnostics Margins

Last FY202420252026202720282029
Gross Margin88%88%88%83%
EBITDA Margin32%34%32%31%
EBIT Margin18%19%18%17%
Net Margin11%12%11%12%
FCF Margin5%8%5%7%

Suraksha Diagnostics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth8%15%21%11%
Gross Profit Growth-17%22%5%
EBITDA Growth7%23%16%9%
EBIT Growth7%37%12%8%
Net Profit Growth19%54%8%19%
FCF Growth73%2%(19%)38%

Data powered by FactSet, Inc. and Morningstar, Inc.

Suraksha Diagnostics Operational KPIs

Suraksha Diagnostics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.

Suraksha Diagnostics' Rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Suraksha Diagnostics' Rule of X is 59% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Suraksha Diagnostics
LTMLast FY202320242025202620272028
Rule of 4048%43%---
Bessemer Rule of X72%59%---
Revenue per Employee-$0.0M---
Opex per Employee-$0.0M---
S&M Expenses to Revenue--2%2%1%
G&A Expenses to Revenue--16%18%16%
Opex to Revenue-71%71%69%70%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Suraksha Diagnostics Competitors

Suraksha Diagnostics competitors include Hyperfine, Biodesix, Centrum Medyczne ENEL-MED, Bioneer, BICO Group, Limes Schlosskliniken, Healius, Exagen, Athens Medical Centre and Frontage Laboratories.

Most Suraksha Diagnostics public comparables operate across Hospitals & Clinics and Laboratory Services.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Hyperfine9.1x7.6x(3.5x)(3.7x)
Biodesix2.3x2.1x(11.7x)(14.1x)
Centrum Medyczne ENEL-MED1.0x-7.8x-
Bioneer0.7x-10.0x-
BICO Group0.8x0.8x65.5x28.5x
Limes Schlosskliniken2.7x2.5x10.9x9.6x
Healius0.8x0.8x5.3x4.5x
Exagen2.0x1.9x(13.6x)(15.0x)

This data is available for Pro users. Sign up to see all Suraksha Diagnostics competitors and their valuation data.

Start Free Trial

Suraksha Diagnostics VC Funding History

Before going public, Suraksha Diagnostics raised $80M in total equity funding, across 3 rounds.


Suraksha Diagnostics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Nov-16Undisclosed stageOrbiMed$40M-Suraksha Diagnostics is a pathology and radiology diagnostic chain based in Kolkata that operates the largest such network in eastern India. The company provides diagnostic services across pathology, cardiology, gastroenterology, neurology and imaging, with operations spanning West Bengal, Bihar, Assam, and Meghalaya. As of 2016, Suraksha operated more than 30 diagnostic centres across the country including polyclinics and sample collection centers. In November 2016, healthcare-focused investment firm OrbiMed announced it was finalizing approximately $40 million in investment into Suraksha Diagnostics. The investment deal closed in December 2016 and comprised both a primary infusion of fresh capital and a secondary purchase of shares from existing PE investor Lighthouse Advisors, which had invested in the company in February 2013. Investment bank o3 Capital advised on the transaction. This marked OrbiMed's first investment in India's eastern region, despite the firm managing over $14 billion in assets globally and having established an India office in 2008. OrbiMed's investment was deployed by Suraksha to expand its laboratory network, purchase new equipment and technologies, and strengthen its technology backbone. The capital raised was aimed at scaling the company's operations in its core geographies of West Bengal, Bihar, and the National Capital Region. By the time of the company's IPO in December 2024, OrbiMed held approximately 33.35% of Suraksha, having invested Rs 164 crore through its December 2016 investment round. Financial data from FY24 (eight years after the 2016 round) showed Suraksha had grown to generate Rs 219 crore in revenue, with 95.48% derived from West Bengal operations. The company posted Rs 74 crore in EBITDA and Rs 23 crore in net profit during that fiscal year, with revenue split between pathology services (53.3%), radiology (46%), and COVID-19 testing (0.18%). However, contemporaneous financial metrics from 2016 are not available in the sources, limiting valuation multiple analysis for the funding round.
Oct-15Series BLighthouse Funds$31M-Suraksha Diagnostics is a leading diagnostic services chain focused on pathology and radiology in East India. Lighthouse Funds invested Rs.30 crore (approximately $4.8 million at 2013 exchange rates) in 2013, achieving 2.3x returns in rupee terms upon exit after nearly four years to OrbiMed Private Limited. The investment supported recruitment of key management, evaluation of strategic acquisitions, and public-private partnership opportunities. The company went public with an IPO raising $99.92 million on December 6, 2024. Lighthouse exited prior to OrbiMed's involvement, noted in the IPO prospectus as a selling shareholder.
Feb-13Series ALighthouse Funds$9M-Suraksha Diagnostics, a Kolkata-based diagnostic chain, raised Rs 50 crore ($9 million) from Lighthouse Funds in February 2013 as its first funding round. Lighthouse Funds invested Rs 30 crore in Suraksha Diagnostic in 2013, later exiting nearly four years later to OrbiMed Private Limited for 2.3x returns in rupee terms. The company operates full-range pathology and radiology services and is the largest diagnostic chain in eastern India, owning about 25 centres across West Bengal, Bihar, Delhi, and the National Capital Region.

Acquisitions by Suraksha Diagnostics

Suraksha Diagnostics has acquired 1 company to date.

Last acquisition by Suraksha Diagnostics was on April 7th 2025. Suraksha Diagnostics acquired Fetomat Wellness for $600K (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Suraksha Diagnostics

Fetomat Wellness
Description
Fetomat Wellness is a healthcare center specializing in advanced pregnancy care and prenatal diagnosis services across communities. It provides antenatal investigations and support to promote safe motherhood and healthy babies through highly trained professionals. Based in Egypt with operations via its Cairo facility, Fetomat Wellness focuses on diagnostic imaging and maternal health services.
HQ CountryIndia
HQ City
Kolkata
Deal Date7 Apr 2025
Valuation$600K
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Suraksha Diagnostics acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Suraksha Diagnostics

When was Suraksha Diagnostics founded?Suraksha Diagnostics was founded in 2005.
Where is Suraksha Diagnostics headquartered?Suraksha Diagnostics is headquartered in India.
How many employees does Suraksha Diagnostics have?As of today, Suraksha Diagnostics has over 1K employees.
Is Suraksha Diagnostics publicly listed?Yes, Suraksha Diagnostics is a public company listed on National Stock Exchange of India.
What is the stock symbol of Suraksha Diagnostics?Suraksha Diagnostics trades under SURAKSHA ticker.
When did Suraksha Diagnostics go public?Suraksha Diagnostics went public in 2024.
Who are competitors of Suraksha Diagnostics?Suraksha Diagnostics main competitors include Hyperfine, Biodesix, Centrum Medyczne ENEL-MED, Bioneer, BICO Group, Limes Schlosskliniken, Healius, Exagen, Athens Medical Centre, Frontage Laboratories.
What is the current market cap of Suraksha Diagnostics?Suraksha Diagnostics' current market cap is $154M.
What is the current revenue of Suraksha Diagnostics?Suraksha Diagnostics' last 12 months revenue is $31M.
What is the current revenue growth of Suraksha Diagnostics?Suraksha Diagnostics revenue growth (NTM/LTM) is 16%.
What is the current EV/Revenue multiple of Suraksha Diagnostics?Current revenue multiple of Suraksha Diagnostics is 5.3x.
What is the current EBITDA of Suraksha Diagnostics?Suraksha Diagnostics' last 12 months EBITDA is $10M.
What is Suraksha Diagnostics' EBITDA margin?Suraksha Diagnostics' last 12 months EBITDA margin is 31%.
What is the current EV/EBITDA multiple of Suraksha Diagnostics?Current EBITDA multiple of Suraksha Diagnostics is 17.0x.
What is the current FCF of Suraksha Diagnostics?Suraksha Diagnostics' last 12 months FCF is $1M.
What is Suraksha Diagnostics' FCF margin?Suraksha Diagnostics' last 12 months FCF margin is 5%.
What is the current EV/FCF multiple of Suraksha Diagnostics?Current FCF multiple of Suraksha Diagnostics is 111.2x.
How many companies Suraksha Diagnostics has acquired to date?As of June 2026, Suraksha Diagnostics has acquired 1 company.
What was the largest acquisition by Suraksha Diagnostics?$600K acquisition of Fetomat Wellness on 7th April 2025 was the largest M&A Suraksha Diagnostics has done to date.
What companies Suraksha Diagnostics acquired?Suraksha Diagnostics acquired Fetomat Wellness.
In how many companies Suraksha Diagnostics has invested to date?Suraksha Diagnostics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Suraksha Diagnostics

Lists including Suraksha Diagnostics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial